Stock Market Reviews

ADTX (Aditxt, Inc.) News

Get the latest news, insights, and market updates on ADTX (Aditxt, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Aditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases
  MOUNTAIN VIEW, Calif., July 29, 2025--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc., ("Pearsanta") has engaged Spartan Capital Securities, LLC ("Spartan") as lead underwriter for its planned Initial Public Offering ("IPO"). This marks an important milestone in Aditxt’s Acquire, Build, and Capitalize ("ABC") strategy, which is designed to accelerate
  Jul 29, 2025 - $ADTX
• Aditxt’s Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test
  MOUNTAIN VIEW, Calif., July 24, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has received an invitation to submit a full proposal for the Congressionally Directed Medical Research Program’s (CDMRP) Ovarian Cancer Research Program ("OCRP") Pilot Award, funded through the U.S. Department of Defense (Funding Opportunity Number: HT942525
  Jul 24, 2025 - $ADTX
• Aditxt to Present at Wall Street Reporter’s Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET
  MOUNTAIN VIEW, Calif., July 22, 2025--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced a live discussion focused on its wholly owned subsidiary Adimune™, Inc. ("Adimune™"), which is advancing therapeutics designed to address autoimmune diseases.
  Jul 22, 2025 - $ADTX
• Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy
  One viral TikTok, 10 million+ views, and a flood of fearless, funny, and unfiltered replies later, a non-hormonal birth control brand — PHEXXI — has found itself at the center of a national conversation on microfeminism. It all started with one unapologetic prompt:
  Jul 15, 2025 - $ADTX
• Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET
  MOUNTAIN VIEW, Calif., June 26, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that Co-founder and CEO Amro Albanna will be presenting at Wall Street Reporter’s NEXT SUPER STOCK livestream event on June 26, 2025 at 1:00 p.m. ET.
  Jun 26, 2025 - $ADTX
• Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors
  MOUNTAIN VIEW, Calif., June 09, 2025--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt’s Board of Directors.
  Jun 9, 2025 - $ADTX
• Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6
  MOUNTAIN VIEW, Calif., June 05, 2025--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt"), a social innovation platform accelerating promising health innovations, today announced that its CEO Amro Albanna will be joined for tomorrow’s Aditxt Weekly Update by Dr. Friedrich Kapp, Chris Mitton, and Evofem Biosciences’ CEO Saundra Pelletier to discuss progress in immune therapy, early disease detection and women’s health, respectively.
  Jun 5, 2025 - $ADTX
• Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
  NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announced that Aditxt, Inc. (“NASDAQ:ADTX”) (“Aditxt”) has delivered notice (the “Termination Notice”) purporting to terminate the arrangement agreement dat
  May 19, 2025 - $ADTX
• Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics
  MOUNTAIN VIEW, Calif., May 19, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that it has determined it is in the best interest of the Company and its stockholders to terminate the previously announced Arrangement Agreement with Appili Therapeutics, Inc.
  May 19, 2025 - $ADTX
• Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™
  MOUNTAIN VIEW, Calif., May 02, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Aditxt’s CIO Dr. Shahrokh Shabahang, and Adimune’s Co-CEO Dr. Friedrich Kapp, will join today’s Aditxt Weekly Update to discuss recent developments related to ADI-100™, the lead therapeutic candidate of its wholly owned subsidiary, Adimune.
  May 2, 2025 - $ADTX